Pulmonx Corp

Pulmonx Corp (LUNG) priced its initial public offering on Oct 1, 2020 at $13.20 per share, below its $17.00–$18.00 range, raising $190M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $447.8M. BofA Securities was lead-left underwriter, joined by Morgan Stanley, Stifel and Wells Fargo and others. Cooley advised the company and A&O Shearman advised the underwriters.

Pulmonx Corp is a commercial-stage medical technology company offering a minimally invasive treatment for severe emphysema, a form of COPD. Its solution combines the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, for patients who remain symptomatic despite medical management.

Status

IPO

Ticker

LUNG

Exchange

Nasdaq Global Select

Priced

Oct 1, 2020

IPO price

$13.20

Price range

$17.00–$18.00

Raised

$190M

Market cap at IPO price

$447.8M

First filed

Feb 28, 2020

Underwriters

BofA Securities, Morgan Stanley, Stifel, Wells Fargo and Canaccord Genuity

Company counsel

Cooley

Underwriters' counsel

A&O Shearman

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.